Rare Disease : Episode 14

Video

Episode 13 - Challenges of Measuring the Outcomes of SLE

During this segment, the panelists discuss treatment options for systemic lupus erythematosus (SLE) and recognize unmet treatment needs from the perspectives of the patient, provider, and payer. To improve patient outcomes, the panelists explore different ways in which treatment for SLE can be improved.

Hugh Fatodu, RPh, MBA, explains that agents currently used to treat SLE are accompanied with adverse events that affect patient adherence, and results of therapy have proven inconsistent amongst certain subgroups of patients. Therefore, clinicians currently question the ability of these agents to provide benefits to their patients.

Michelle Petri, MD, MPH, explains the ways in which long-term exposure of prednisone affects patient outcomes. Dr Petri also believes that a personalized treatment approach is necessary when treating patients.

And because long-term data is still lacking, Maria Lopes, MD, MS, believes that an early diagnosis of SLE is essential, as outcomes of severe SLE are more dangerous.


Related Videos
Sam Peasah, PhD, MBA, RPh, director for the Center of High-Value Health Care at the University of Pittsburgh Medical Center (UPMC)
Pierluigi Porcu, MD
Image credit: Medical technology and futuristic concept. Doctor hologram modern virtual screen interface | SOMKID - stock.adobe.com
JC Scott, CEO and president of The Pharmaceutical Care Management Association (PCMA)
Elizabeth Grush, MBA
Cathy Eng, MD, FACP, FASCO, Vanderbilt-Ingram Cancer Center
Erin Weber, MS
Kenny Cole, MD
Neha Kashalikar, PharmD, director of strategic pharmacy consulting, MassHealth
Related Content
AJMC Managed Markets Network Logo
CH LogoCenter for Biosimilars Logo